Lexeo Therapeutics
Presence
Acquisition, funding and merger involving Lexeo Therapeutics.
- Lexeo Therapeutics has just announced a $100 Million fundraising (posted on November 6 2023).
Executives
View the org chart displaying its 18 main executives
Most searched biographies at Lexeo Therapeutics
- Nolan Townsend, Chief Executive Officer and Director
- Mette Kirstine Agger, Director
- Rajiv Patni, Director
Popular executive movements at Lexeo Therapeutics
- Sandi See Tai, who was Senior Vice President, Clinical Development and Operations, is promoted to Chief Development Officer (posted on February 6 2024).
- Rajiv Patni has joined the company as Director (posted on February 6 2024).
- Eric Adler, who was Chief Scientific Officer, is promoted to Chief Medical Officer & Head of Research (posted on February 6 2024).
Create your alert
to follow the executive moves at Lexeo Therapeutics.
Biotechnology
Lexeo Therapeutics has 2,276 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
Popular contacts in Biotechnology
News
Press releases by Lexeo Therapeutics
- Press releases - Lexeo
- Press releases - Lexeo
- Press releases - Lexeo
- LEXEO Launches with $85 Million in Series A Funding
- LEXEO Launches with $85 Million in Series A Funding
- Press Releases
- View more press releases Close
Social media about Lexeo Therapeutics
- Lexeo Therapeutics on Wikipedia, Google News & Yahoo Finance
- Lexeo Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Bernard Davitian 
Call Lexeo Therapeutics at +1 ...
